Does BROLUCIZUMAB-DBLL Cause Blindness transient? 99 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 99 reports of Blindness transient have been filed in association with BROLUCIZUMAB-DBLL. This represents 3.5% of all adverse event reports for BROLUCIZUMAB-DBLL.
99
Reports of Blindness transient with BROLUCIZUMAB-DBLL
3.5%
of all BROLUCIZUMAB-DBLL reports
1
Deaths
9
Hospitalizations
How Dangerous Is Blindness transient From BROLUCIZUMAB-DBLL?
Of the 99 reports, 1 (1.0%) resulted in death, 9 (9.1%) required hospitalization.
Is Blindness transient Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BROLUCIZUMAB-DBLL. However, 99 reports have been filed with the FAERS database.
What Other Side Effects Does BROLUCIZUMAB-DBLL Cause?
Vitreous floaters (479)
Visual impairment (446)
Vision blurred (416)
Eye inflammation (387)
Visual acuity reduced (365)
Retinal vasculitis (323)
Uveitis (305)
Vitritis (284)
Eye pain (234)
Vitreous opacities (205)
What Other Drugs Cause Blindness transient?
AFLIBERCEPT (987)
ADALIMUMAB (200)
METFORMIN (153)
DIMETHYL (119)
INTERFERON BETA-1A (102)
NATALIZUMAB (101)
RANIBIZUMAB (100)
FINGOLIMOD (89)
BEVACIZUMAB (72)
DUPILUMAB (59)
Which BROLUCIZUMAB-DBLL Alternatives Have Lower Blindness transient Risk?
BROLUCIZUMAB-DBLL vs BROMAZEPAM
BROLUCIZUMAB-DBLL vs BROMFENAC
BROLUCIZUMAB-DBLL vs BROMHEXINE
BROLUCIZUMAB-DBLL vs BROMOCRIPTINE
BROLUCIZUMAB-DBLL vs BROTIZOLAM